Resolution No. 6/23-1

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT INFLUENZA

The purpose of this resolution is to (1) update the product table in the IIV component of the resolution, (2) update the eligible groups section of the LAIV component of the resolution, and (3) add/update the links in the contraindications and precautions section of both components of the resolution.

VFC resolution 6/21-2 is repealed and replaced by the following:

Inactivated Influenza Vaccine (IIV)

Eligible Groups

All children aged 6 months through 18 years.

Recommended Vaccination Schedule and Intervals

- 6 months through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose
- Minimum Age: 6 months
- Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

The table below lists the currently approved inactivated influenza vaccines in the VFC program, including the age indication for each vaccine.

Brand Name (1)	Presentation	Age Indication
Afluria (Trivalent) (2)	0.5 mL pre-filled syringe	≥ 36 months
Afluria (Trivalent) (2)	5.0mL multi-dose vial	≥6 months
Fluarix (Trivalent) (2)	0.5 mL pre-filled syringe	≥ 6 months
Flucelvax (Trivalent) (2,3)	0.5 mL pre-filled syringe	≥6 months
Flucelvax (Trivalent) (2,3)	5.0mL multi-dose vial	≥6 months
Flulaval (Trivalent) (2)	0.5 mL pre-filled syringe	≥ 6 months
Fluzone (Trivalent) (2)	0.5mL prefilled syringe/single-dose vial	≥ 6 months
Fluzone (Trivalent) (2)	5.0mL multi-dose vial	≥ 6 months

Notes:

(1) The use of brand names is not meant to preclude the use of other comparable licensed vaccines.

(2) Resolution was updated 6/28/2024 to reflect FDA's recommendation for trivalent influenza vaccines to be used for the 2024-2025 season; see Use of Trivalent Influenza Vaccines for the

2024-2025 U.S. Influenza Season | FDA.
(3) All IIVs and LAIV are egg-based, with the exception of Flucelvax Quadrivalent, which is cell culture-based.

Recommended Dosage

Refer to product package inserts available at:
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states

Contraindications and Precautions

Contraindications:

1. For egg-based IIV: History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (other than egg) or after previous dose of any influenza vaccine.
2. For cell culture-based IIV: history of severe allergic reaction (e.g., anaphylaxis) to cell culture-based IIV or any component of the vaccine.

Precautions:

1. Moderate or severe acute illness with or without fever
2. GBS within 6 weeks following a previous dose of influenza vaccine
3. For cell culture-based IIV only: History of severe allergic reaction to any other influenza vaccine.

Details of contraindications and precautions can be found at Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season.

Live Attenuated Influenza Vaccine (LAIV3)(1)

Eligible Groups

All healthy, non-pregnant children and adolescents (those who do not have an underlying medical condition that predisposes them to influenza complications) aged 2 through 18 years.

Recommended Vaccination Schedule and Intervals

- 2 years through 8 years: 1 or 2 doses, as noted in the current ACIP recommendations
- 9 through 18 years: 1 dose
- Minimum Age: 2 years
- Minimum interval between dose 1 and dose 2 (where applicable): 4 weeks

Recommended Dosage

Refer to product package insert.

Contraindications and Precautions

Contraindications and precautions can be found at:
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season |

MMWR (cdc.gov)

[If an ACIP recommendation regarding influenza vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the URL.]

Adopted and Effective: June 21, 2023

This document can be found on the CDC website at:
https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html